Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluoroquinolones Clear all
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 25, 2026, 6:58 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

NCT00721344
View directory record Official record
Conditions
Healthy Subjects
Interventions
Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2012 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 25, 2026, 6:58 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

NCT00645073
View directory record Official record
Conditions
Acute Bacterial Sinusitis
Interventions
cefdinir (Omnicef), levofloxacin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
23
States / cities
Birmingham, Alabama • Columbiana, Alabama • Eclectic, Alabama + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cholera Anti-Secretory Treatment Trial

NCT04150250
View directory record Official record
Conditions
Cholera
Interventions
iOWH032, Placebo, V. cholerae Challenge, Antibiotics
Drug · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 44 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 25, 2026, 6:58 PM EDT
Terminated Not applicable Interventional Results available

Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy

NCT02247960
View directory record Official record
Conditions
Prostate Cancer, Urinary Tract Infection, Clostridium Difficile
Interventions
Ciprofloxacin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 25, 2026, 6:58 PM EDT
Withdrawn Phase 4 Interventional

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

NCT03891979
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pembrolizumab, Ciprofloxacin 500mg PO BID days 1-29, Metronidazole 500mg PO TID days 1-29
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Months to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 25, 2026, 6:58 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

NCT03303677
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Saline Nasal, Budesonide Nasal, Topical Antibacterial (Product)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots

NCT01976065
View directory record Official record
Conditions
Pulp Necrosis, Regeneration
Interventions
Triple Antibiotic Paste, Standard Treatment
Drug · Other
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
6 Years to 20 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
4
States / cities
Loma Linda, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

NCT05355935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Brensocatib, Moxifloxacin, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

NCT00518089
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Gatifloxacin 0.5% eye drops, placebo eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
1 Year and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Downey, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers

NCT01514929
View directory record Official record
Conditions
Cardiac Effects in Normal Healthy Volunteers
Interventions
ACHN-490 Injection, Moxifloxacin, Placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 25, 2026, 6:58 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

NCT05286931
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Ciprofloxacin 500 mg
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

NCT05878522
View directory record Official record
Conditions
Healthy
Interventions
sisunatovir, placebo, moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 25, 2026, 6:58 PM EDT
Terminated No phase listed Observational

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

NCT01189864
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 25, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 25, 2026, 6:58 PM EDT